Gastrointestinal Cancer

Liposomal Irinotecan Improves Upon 5-FU/LV in Refractory Pancreatic Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date October 4, 2022

Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.

Oral CDK7 Inhibitor Granted Orphan Drug Status for Pancreatic Cancer

By

Brian Park, PharmD

Publish Date September 29, 2022

SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7.

Neoadjuvant Nivolumab-Ipilimumab Could Be New Standard Care in dMMR Colon Cancer

By

Vicki Moore, PhD

Publish Date September 27, 2022

Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.

Fruquintinib Potentially Practice-Changing in Refractory Metastatic Colorectal Cancer

By

Jessica Nye, PhD

Publish Date September 23, 2022

Adding fruquintinib to best supportive care improved progression-free survival and overall survival in the FRESCO-2 trial.

Risks of Second Primary Malignancies Increased in Colorectal Cancer Survivors

By

Vicki Moore, PhD

Publish Date September 16, 2022

A systematic review and meta-analysis sought to determine the risk of secondary primary cancer for survivors of colorectal cancer.